Bladder Cancer
5 videos · updated daily
47:18 Urologic Cancer Trials From GU ASCO and ASCO
Dr. Hanan Goldberg reviews four trials from GU ASCO and ASCO 2026, KEYNOTE-B15 (EV-304), LITESPARK-022, PROTEUS and TALAPRO-3, in bladder, kidney and prostate cancer, and their limitations, at the UroCancer Interdisciplinary Forum.
26:31 Bladder Cancer Readouts from ASCO 2026
Dana-Farber's Lank Center for Genitourinary Oncology summarises bladder cancer readouts from ASCO 2026, including the POTOMAC trial of durvalumab plus BCG, EV-302 of enfortumab vedotin plus pembrolizumab, and the NEXUS01 Nectin-4 ADC study.
13:23 Endpoints and Trial Designs for Bladder Cancer
Amirali Salmasi, MD, discusses risk stratification, definitions, endpoints and clinical trial designs for bladder cancer research, for Grand Rounds in Urology.
1:02:06 Real-World Evidence in Precision Oncology
IDDI considers the statistical implications of large uncontrolled early-phase expansion cohorts in immune checkpoint inhibitor trials, accelerated approval withdrawals in bladder cancer, and the potential role of real-world evidence in precision oncology.
58:46 [LTRN Webinar] Inside the Data - LP-184 Phase 1a Results and Future Trials with Dr. Igor Astsaturov
Lantern Pharma and Dr. Igor Astsaturov of Fox Chase Cancer Center review Phase 1a results for LP-184, a synthetic lethal candidate for advanced solid tumours, and plans for further trials.